HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology3 papers

Amegakaryocytic thrombocytopenia

Last edited: 4/22/2026

Overview

Amegakaryocytic thrombocytopenia is a rare hematologic disorder characterized by a severe deficiency of megakaryocytes, leading to markedly reduced platelet production and significant bleeding tendencies 1.

Diagnosis

  • Bone marrow examination showing markedly reduced or absent megakaryocytes 1
  • Severe thrombocytopenia (platelet count typically <50,000/μL) 1
  • Evidence of spontaneous or trauma-induced bleeding 1

    • Management

  • First-line treatments: Platelet transfusions, often requiring HLA-matched donors 1
  • Adjunctive treatments: Aminocaproic acid for control of hemorrhage 1
    • - Dose and duration not specified, but effective in reducing bleeding episodes 1 - Monitor for orthostatic hypotension, manageable with dosage adjustments 1

    Special Populations

  • No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.

    • Key Recommendations

  • Consider aminocaproic acid for managing bleeding complications in patients with amegakaryocytic thrombocytopenia to reduce the need for platelet transfusions (Evidence: Moderate) 1
  • Monitor for and manage orthostatic hypotension when administering aminocaproic acid (Evidence: Weak) 1
  • Continue to prioritize HLA-matched platelet transfusions as a primary management strategy (Evidence: Expert opinion) 1

    • References

    1 Gardner FH, Helmer RE. Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA 1980. link

    Original source

    1. [1]
      Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. — Gardner FH, Helmer RE JAMA (1980)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG